This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.

Start Date01 Jul 2026

Sponsor / Collaborator

Thomas Jefferson University

[+4]

NCT07645599

/ Not yet recruitingNot ApplicableIIT

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

This pilot study is testing a new ultrasound imaging method called Super-Resolution Ultrasound (SRU) to look at blood flow and tiny blood vessels in transplanted kidneys in very detailed images after kidney transplant surgery. The goal is to see whether changes in the kidney's small blood vessels can help predict how well the transplanted kidney will work early after transplant, including whether delayed graft function may occur.
Investigators hope this technique can become a safe, noninvasive way to evaluate transplanted kidneys without needing as many invasive biopsies. It may also help doctors better assess donor kidneys at higher-risk of suboptimal functioning.

Start Date01 Jun 2026

Sponsor / Collaborator

University of Pittsburgh

NCT07436364

/ RecruitingEarly Phase 1IIT

Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy

This pilot study will evaluate the feasibility of applying CEUS as imaging guidance for planning RT and predicting RT response. The investigators will determine if US-CT/MRI fusion is feasible and if tumor vascularity and pressure from CEUS can be used to reflect/predict the RT response.
The investigators will perform CEUS three times: before the first neoadjuvant RT fraction, halfway through RT, and between the completion of RT and surgery. The fusion will be performed using previously acquired CT/MRI or on-site cone-beam CT with Bmode US. Once the fusion is successful, CEUS will be performed and panoramic 2D images (mimicking 3D) will be collected for the whole tumor. If the fusion is not feasible or successful, the investigators will perform CEUS side by side with CT/MRI and collect images. The investigators will quantify tumoral vascularity comparing Bmode area/volume (total tumor) and contrast-enhanced area/volume (vascular region) at each time point. Subharmonic amplitudes in the tumor area/volume will be quantified to estimate tumoral pressure (known to be the same level as interstitial fluid pressure (IFP)). Quantified vascularity and pressure at each time point will be compared with the tumor size change at later study points as well as the histological outcome after the surgery.

Start Date23 Mar 2026

Sponsor / Collaborator

Thomas Jefferson University

100 Clinical Results associated with Perflutren lipid microsphere

100 Translational Medicine associated with Perflutren lipid microsphere

100 Patents (Medical) associated with Perflutren lipid microsphere

1,246

Literatures (Medical) associated with Perflutren lipid microsphere

01 Jul 2026·ULTRASOUND IN MEDICINE AND BIOLOGY

Nonlinear Response of Phospholipid-Shelled Ultrasound Contrast Agents: Ambient Conditions Affect Temporal Evolution

Article

Author: Kaushik, Anuj ; Menon, Surabhi Jagadeesh ; Shekhar, Himanshu ; K S, Manu

OBJECTIVE:

Non-linear cavitation response from ultrasound contrast agents (UCAs) is sensitive to ambient conditions. Recent studies have shown that the cavitation response can exhibit a delayed onset of non-linear spectral peaks and can evolve over time, on the order of several tens of minutes. However, the effect of ambient conditions on the temporal evolution of UCAs has not been explored previously. Elucidating this behavior is essential for standardizing acoustic measurement protocols. This study characterized the impact of temperature, hydrostatic overpressure and the presence of dissolved protein in the solution on the temporal evolution of the non-linear acoustic response of two clinically approved UCAs, Definity and SonoVue, and a modified agent, octafluoropropane-substituted SonoVue (OFP-SonoVue). These ambient conditions are relevant for understanding how the UCA response may be affected in conditions relevant to laboratory studies as well as in vivo.

METHODS:

A custom 2 MHz single-element transducer (focal number of 1.26, fractional bandwidth 4.26%) was used to excite the diluted bulk UCA suspension at a peak rarefactional pressure of 470 kPa. A 50-cycle sine burst excitation was employed at a pulse repetition frequency of 1 kHz. A confocally aligned broadband transducer with a center frequency of 20 MHz, 6 mm aperture and a fractional bandwidth of 92.69% was used to receive the scattered echoes. The cavitation response from the UCAs was first evaluated at 25°C and 37°C in de-ionized water at atmospheric pressure. Next, the effect of static overpressure (40 mm Hg) was determined at 25°C. Finally, the effect of dissolved protein content was assessed by performing measurements in a 0.5% w/v bovine serum albumin solution at room temperature and atmospheric pressure.

RESULTS:

The agents exhibited starkly different non-linear responses over time under the tested ambient conditions. Definity demonstrated sub-harmonic onset at 16, 6, 0 and 0 min after the start of ultrasound exposure at 25°C, 37°C, with overpressure and with added protein, respectively. In comparison, SonoVue exhibited an instantaneous or near-instantaneous sub-harmonic onset following ultrasound exposure (at 0, 0, 1 and 0 min). For the modified OFP-SonoVue agent, the corresponding sub-harmonic onset times were 0, 0, 5 and 0 min. The time to attain peak responses for various non-linear modes (sub-harmonic, ultra-harmonic and second harmonic) and their respective amplitudes also varied considerably across ambient conditions for the three agents.

CONCLUSION:

Definity demonstrated a strong sensitivity to ambient conditions, whereas SonoVue displayed greater robustness across environments. Results from OFP-SonoVue suggest that the temporal response at physiological temperature and in protein-rich media is primarily determined by the lipid shell, whereas with overpressure, it is predominantly filling gas dependent. These results highlight fundamental differences in the response of these UCAs and help understand sources of variability in UCA response for specific applications in imaging, sensing and therapy.

06 May 2026·RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Human Amniotic Membrane (hAM) in Macular Hole Repair: A Scoping Review

Article

Author: Cheffi, Nadine ; Mandelcorn, Efrem ; Gao, Angel ; Felfeli, Tina ; Solish, Danielle

Purpose::

This scoping review examines the technique and outcomes for human amniotic membrane (hAM) grafts in macular hole (MHs) repair, an emerging alternative to conventional methods involving pars plana vitrectomy (PPV), internal limiting membrane (ILM) peeling, and gas endotamponade.

Methods::

A literature search of three databases was conducted on December 5, 2025.

Results::

66 studies involving 603 eyes were included. Most hAMs were sourced from eye banks or private companies and cut into 1-4 mm grafts using punch biopsies. All participants underwent PPV with ILM peeling. Grafts were commonly placed stromal side down using forceps, viscous injectors or under fluid or perfluorocarbon liquid. Endotamponade agents included SF6, C3F8, and silicone oil. The overall MH closure rate was 96%. Fresh hAM achieved a 100% closure rate, while cryopreserved hAM achieved 95%. Visual improvement was reported in 81% of cases, with the highest gains observed in traumatic MHs. Myopic MHs with retinal detachments had the lowest closure rate (72%). Graft dislocation was the most common complication (3.6%), and no systemic or uveitic complications were reported.

Conclusion::

hAM grafting demonstrates high anatomical success and visual improvement with minimal complications, suggesting utility in MH repair, particularly in complex or refractory cases.

08 Apr 2026·RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Choosing the Optimal Tamponade in Silicone Oil Removal: A Comparative Analysis of BSS, Air, and C3F8

Article

Author: Hu, Jie ; Huang, Jiaqi ; Jiang, Zhihao ; Jiang, Xintong

Purpose::

To compare the effects of balanced salt solution (BSS), air, and perfluoropropane (C3F8) as intraocular tamponade agents on visual acuity and intraocular pressure (IOP) following silicone oil (SO) removal surgery.

Methods::

This retrospective study included 60 eyes that underwent 23-gauge SO removal and were assigned to the BSS, air, or 8% C3F8 groups (n = 20 per group). Best-corrected visual acuity (BCVA) and IOP were evaluated postoperatively at day 1, week 1, month 1, and month 3.

Results::

On postoperative day 1, the BCVA was significantly better in the BSS group than in the air and C3F8 groups (P<0.001). At 1 week, BCVA in the air group improved to a level comparable with that in the BSS group (P=0.225), while the BCVA in C3F8 group remained worse than that in both groups (P<0.001 vs. BSS; P=0.009 vs. air). At 1 and 3 months, BCVA did not differ significantly between the BSS and air groups (P=0.204 vs. 1 month; P=0.168 vs. 3 months) but remained lower in the C3F8 group (all P<0.05). No significant differences in IOP were found between groups at any time point.

Conclusion::

BSS provides the fastest visual recovery after SO removal compared to air and C3F8. It is the optimal choice for improving both short- and long-term visual outcomes while maintaining normal IOP in routine cases.

News (Medical) associated with Perflutren lipid microsphere

26 May 2026

·www.fiercepharma.com

Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium: Bloomberg

Lantheus reported $377.3 million in worldwide revenues over the first quarter of 2026, reflecting sales of its roster of radiodiagnostic imaging agents. A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a buyout offer from Curium Pharma, Bloomberg reported on Friday. Curium’s proposal values Massachusetts-based Lantheus at about $7 billion, the news outlet said, citing people familiar with the matter. The deal could be weeks away, but a final discussion has not yet been made and no agreement is guaranteed, according to Bloomberg. Lantheus does “not comment on market rumors or speculation” as a matter of policy, a spokesperson told Fierce Pharma on Tuesday. For its part, Curium “operates in a highly competitive environment and, like all companies, is always evaluating organic and external pathways to better serve our patients and customers,” a company representative said in an emailed statement. At the same time, the representative also caveated to Fierce that Curium “does not comment on market rumors or speculation.” Last year, Curium had a hand in what was the “largest transaction in nuclear medicine globally” when its majority owner, global investment firm CapVest, raised money to recapitalize Curium through a new continuation vehicle that similarly valued the radiopharmaceutical company at $7 billion. The investor base that chipped in reflected a “strong belief in the future trajectory of the company in a market poised for exponential growth in the next 15 years,” Curium said at the time. Lantheus, meanwhile, has recently been on the other side of the dealmaking table with an acquisition spree of its own. Early last year, the radiopharmaceutical specialist shelled out $250 million in upfront cash to take on Evergreen Theragnostics, committing up to $752.5 million in additional potential milestone payments. The union of Evergreen’s manufacturing capabilities and infrastructure with Lantheus’ radiopharmaceutical digs was meant to help the company “meet the complex demands of radiopharmaceutical development and production,” Lantheus said, and it also adds new candidates to the company's oncology diagnostic pipeline. Other recent acquisitions for Lantheus include Meilleur Technologies and its Alzheimer’s disease PET imaging agent, plus Life Molecular Imaging and its approved F-18 PET imaging agent Neuraceq, along with broader Alzheimer’s radiodiagnostic commercial infrastructure. While being “disciplined in our capital deployment” and prioritizing radiodiagnostics while weighing the “best path to maximize value from our radiotherapeutic assets,” Lantheus is looking to “lay the groundwork for growth acceleration beginning in 2027,” interim CEO Mary Anne Heino said in the company’s first quarter earnings release. The radiopharma reported $377.3 million in worldwide revenues over the first quarter of 2026, backed largely by Neuraceq, the ultrasound-enhancing agent Definity and the prostate cancer diagnostic imaging agent Pylarify. Meanwhile, next month will see the expiration of a 30-month stay that will allow for approval of Lantheus' radioequivalent version of Novartis’ gastroenteropancreatic neuroendocrine tumor-fighting Lutathera, which the FDA granted a tentative approval in March. Radiopharmaceuticals, or drugs made using small amounts of radioactive material, have quickly risen in popularity. Just last week, radioisotope supplier Niowave broke ground on a new $75 million facility in Lansing, Michigan, that will see multiple superconducting linear accelerators and state-of-the-art processing and quality systems to facilitate the increased production of alpha-emitting isotope Actinium-225 (Ac-225). The class of nuclear medicines can be used in both therapeutic and diagnostic roles.

AcquisitionDrug Approval

21 Oct 2024

·www.nuvoxtherapeutics.com

NuvOx Announces Two New Publications

NuvOx Announces Two New Publications Tucson, AZ – October 21, 2024 - Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine efforts to publish 2 journal articles that help explain how the NuvOx drug candidate - NanO2TM works. Artificial Cells, Nanomedicine, and Biotechnology published Dodecafluoropentane emulsion as an oxygen therapeutic, an article that explains NanO2’s mechanism of action of delivering oxygen. The British Journal of Cancer Research published A Phase 2 Double-Blind, Randomized, Prospective, Placebo Controlled Study of NanO2TM Combined with Radiation and Temozolomide in Patients with Newly-diagnosed Glioblastoma Multiforme; RESTORE, an article that details the clinical trial design of NuvOx’s Phase 2b study using NanO2 to treat an extremely aggressive form of brain cancer. Dr. Unger is a radiologist that developed the world’s leading ultrasound contrast agent, Perflutren, a microbubble product, which was FDA approved July 31st, 2001 and is marketed as Definity®. Since that time, Dr. Unger has continued research on microbubbles which led to the discovery of nanobubbles as oxygen therapeutics, now developed as NanO2TM. “Planning a clinical trial is difficult. We put a huge amount of time and thought into planning RESTORE and it’s rewarding to be able to involve the rest of the scientific community in our work by sharing our clinical trial protocol publicly,” said Dr. Unger. “We have only scratched the surface of what is possible and I am inspired by the cancer patients we treat every day. We don’t want to just make a difference; we want to make the kind of impact that keeps families together and gives them more time with their loved ones”. Dr. Johnson is an experienced pharmaceutical scientist having formulated various transdermal, intravenous and orally administered drugs over the past 25 years. Her hard work and expertise afforded NuvOx a patent on the formulation for NanO2. She said, “I have always wanted to write an article that contains the answers to questions about oxygen delivery that I most often get asked. I am extremely happy to have been given this opportunity and my hope is that it is written well enough to educate the public on the exciting things we can do to enhance lives here at NuvOx.” She went on to say, “Our first priority is to help patients live more healthy, productive and enjoyable lives and I am thrilled to be a part of that goal.” About NuvOx: NuvOx is a privately held clinical stage biopharmaceutical company developing a novel platform of oxygen therapeutics for the treatment of diseases where hypoxia plays a role. Hypoxia, or low oxygen, is responsible for resistance to cancer treatment, brain damage in stroke, and the death of patients with acute respiratory distress syndrome (ARDS). The Company’s drug candidate- NanO2 represents a disruptive platform technology addressing multiple unmet needs, with positive results demonstrated in two completed Phase Ib/II studies: one in glioblastoma as a radiosensitizer and the other in stroke as a neuroprotectant. It was shown to be the most promising oxygen therapeutic among 74 clinical-stage compounds in literature review. It has safety and efficacy data in 7+ indications in various preclinical and clinical stages, including Orphan Drug Designation for both glioblastoma and sickle cell anemia. The product can refer to safety data in ~2,000 subjects. The product is designed to be synergistic, rather than competitive with standard of care. The company also has a strong IP portfolio: 11 Patent Families; 11 issued US patents and 32 foreign equivalents. NuvOx is conducting a Phase IIb clinical trial as a radiosensitizer in treatment of glioblastoma, and also plans to start a Phase IIb clinical trial for NanO2 in treatment of acute ischemic stroke, and a Phase Ib clinical trial for NanO2 in treatment of respiratory distress. NuvOx Contact: Rong Wang, President and CEO rwang@nuvoxpharma.com Forward looking statement Certain statements in this release may constitute “forward-looking statements.” When used in this release, words like “may,” “will,” “can,” “should,” “expect,” “anticipate,” “believe,” “project,” or “intend” and other similar expressions are intended to identify forward-looking statements. Statements regarding future events and developments and future performance, as well as our expectations, beliefs, plans, or projections, including statements regarding the exciting things NuvOx can do to enhance lives and help patients live more healthy, productive and enjoyable lives, are forward-looking statements which reflect only our predictions, assumptions, and estimates regarding future events and circumstances. Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.

Phase 2Orphan DrugDrug Approval

22 Jul 2022

·www.sciencedaily.com

Porous crystals bind fluorine-containing greenhouse gases

Fluorine-containing gases -- including so-called per- or polyfluorinated hydrocarbons, or PFCs -- have a significant share in global warming. Researchers recently developed new crystalline materials that can selectively adsorb the molecules of such carbon-fluorine bonds. They hope that these porous crystals may be useful for targeted binding and recovery of PFCs. Emissions of greenhouse gases contribute significantly to global warming. Not only carbon dioxide (CO2) but also fluorine-containing gases -- including so-called per- or polyfluorinated hydrocarbons, or PFCs -- have a significant share in this development. Researchers at the Institute of Organic Chemistry of Heidelberg University led by Prof. Dr Michael Mastalerz recently developed new crystalline materials that can selectively adsorb the molecules of such carbon-fluorine bonds. The Heidelberg researchers hope that these porous crystals may be useful for targeted binding and recovery of PFCs. Polyfluorinated carbons are organic compounds of various lengths in which the hydrogen atoms of alkanes are partly or fully replaced by fluorine atoms. These atoms are chemically highly stable. They are not ubiquitous in nature and are used mainly for etching processes in the semiconductor industry, in eye surgery, and in medical diagnostics as contrast enhancers for certain ultrasound examinations. "Unlike CO2, which is integrated in natural material cycles, PFCs accumulate in the atmosphere and stay there for several thousands of years before breaking down," stresses Prof. Mastalerz. Compared to carbon dioxide, PFCs thus have a much greater global warming potential -- the impact of one PFC molecule is virtually equal to 5,000 to 10,000 CO2 molecules. According to the researcher, that makes polyfluorinated hydrocarbons a permanent problem that is not only contributing to global warming now but accelerating it as well. With his research group at the Institute of Organic Chemistry of Heidelberg University, Prof. Mastalerz has developed a new type of crystalline material that can adsorb polyfluorinated hydrocarbons highly selectively, i.e., binding them to its interior surface. The porous crystals are based on shape-persistent organic cage compounds that carry fluorine-containing side chains on the interconnected struts. These side chains react according to the "like attracts like" principle via fluorine-fluorine interactions with the PFC molecules, ensuring they are deposited on the inner surface of the material. In their experiments, the Heidelberg researchers proved that the crystals they developed bind certain fluorine-containing gases such as octafluoropropane or octafluorocyclobutane approximately 1,500 to 4,000 times more strongly than dinitrogen, the main component of air. According to Prof. Mastalerz, these numbers represent extraordinarily high selectivities to bind such PFCs. Currently Prof. Mastalerz and his team are working on further increasing the selectivity of the crystals and transferring the process to other fluorinated gases, such as those used in medical anaesthesia. "I see enormous potential for development in this area," emphasises the researcher. He hopes that the adsorbent can be used for recovery of polyfluorinated hydrocarbons at their point of use. The German Research Foundation funded the research.

100 Deals associated with Perflutren lipid microsphere

External Link

KEGG	Wiki	ATC	Drug Bank
D01738	Perflutren lipid microsphere	V08DA04	DB00556

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	15 Nov 2022
Contrast agents	United States	Lantheus Medical Imaging, Inc.	31 Jul 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Exertional Compartment Syndrome	Phase 3	United States	Lantheus Medical Imaging, Inc.	01 Jul 2020
Kidney Diseases	Phase 3	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	10 Nov 2017
Kidney Diseases	Phase 3	China	Lantheus Medical Imaging, Inc.	10 Nov 2017
Pyonephrosis	Phase 3	China	Lantheus Medical Imaging, Inc.	10 Nov 2017
Pyonephrosis	Phase 3	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	10 Nov 2017
Renal Cell Carcinoma	Phase 3	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	10 Nov 2017
Renal Cell Carcinoma	Phase 3	China	Lantheus Medical Imaging, Inc.	10 Nov 2017
Liver Diseases	Phase 3	China	Lantheus Medical Imaging, Inc.	21 Sep 2017
Liver Diseases	Phase 3	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	21 Sep 2017
Hepatocellular Carcinoma	Phase 3	United States	Lantheus Medical Imaging, Inc.	01 Apr 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04056988 (CTgov)	Phase 4	Nerve injury \| acute spinal cord injury	27	Perflutren Lipid Microsphere	mtrewiylms(zyamcxnuht) = icqidvpddj xlkhpntrhs (whvwkkibco, cvfkdhkdwi - ihwikjljxc) View more	-	29 Apr 2026
NCT04721886 (CTgov)	Early Phase 1	Breast Cancer	25	Contrast - Enhanced Ultrasound+Perflutren Lipid Microcpheres	ggoxyuuwlz = wkqkqufgrf nwhcavnhce (cjodtuznmu, oqxygtotvi - lkoxbkebsp) View more	-	02 Apr 2026
NCT04136912 (CTgov)	Phase 2	Breast Cancer \| Thyroid Cancer	27	Acoustic Angiography+Definity (Breast Imaging Cohort)	pyyexrhqwx = bkglmejnpu spsbehkqsl (wlrmliqjvu, dwubclxpub - fuuaodghcf) View more	-	15 Sep 2025
				Acoustic Angiography+Definity (Thyroid Imaging Cohort)	tnifpieghg(xvvrbpriun) = extjskklva ehyqjhddhy (nypeobzkpd, gqsggftjcu - auryqsoxam) View more
NCT04185246 (CTgov)	Phase 1/2	Heart Defects, Congenital \| Heart Diseases	36	NH002 (Cohort 1)	zojspbqvbl(wjqyjpipsz) = gohjebpgfc zydqasrafc (plrgdsyjla, 19.37) View more	-	20 Dec 2024
				NH002 (Cohort 2)	zojspbqvbl(wjqyjpipsz) = xcurltzqbm zydqasrafc (plrgdsyjla, 24.07) View more
NCT01835067 (Pubmed \| JAMA Ophthalmol)	Phase 2/3	Age Related Macular Degeneration	56	Intravitreal Tissue Plasminogen Activator (TPA)	seestmjcbg(cerdgsriqf) = xrcjcqvtpx nxpbclgtmj (dkvuqnahuy )	Positive	01 Dec 2024
				Perfluoropropane (C3F8)	seestmjcbg(cerdgsriqf) = ancdhldihc nxpbclgtmj (dkvuqnahuy )
NCT01835067 (TAPAS, EURETINA2024)	Phase 2/3	Age Related Macular Degeneration	56	C3F8	epywgjquqf(qehxgxxcwq) = klghxynbhu yfoyvtbzda (acmiprnwwu )	Positive	19 Sep 2024
				TPA	epywgjquqf(qehxgxxcwq) = jnmnbiqoaw yfoyvtbzda (acmiprnwwu )
NCT04118764 (CTgov)	Not Applicable	Alzheimer Disease	6	Neuronavigation-guided single-element focused ultrasound transducer+Amyvid+Definity	mdiyrgsuba = pgpgtprqii vcwcugsnoz (crgquuejkz, dneejxqcbl - wcroqbosrq) View more	-	26 Aug 2024
CTR20171087 (Pubmed \| BMC Pharmacol Toxicol)	Phase 1	-	-	perflutren lipid microsphere injection (DEFINITY®) (Male subjects)	rtncxdefvj(zqejbwrepu) = hrqptlvopg wmubpmbhgb (dwtndyeiow ) View more	-	02 Jan 2024
				perflutren lipid microsphere injection (DEFINITY®) (Female subjects)	rtncxdefvj(zqejbwrepu) = jvdktemaym wmubpmbhgb (dwtndyeiow ) View more
NCT02764801 (CTgov)	Phase 3	Hepatocellular Carcinoma	131	Logiq E9 Scanner (Contrast-enhanced ultrasound)+Ultrasound contrast agent (Contrast-enhanced ultrasound)	xfjjotyjgc = uvkdhvihse nadwmnojym (isaksourus, atwpidhshn - vinrtdmzpr) View more	-	21 Sep 2023
NCT02424955 (CTgov)	Not Applicable	Hepatocellular Carcinoma	11	3D ultrasound+perflutren lipid microspheres	dsahhrwmoz(tgvmklnidr) = hbzrzbgtuc vekqlnkjiu (oobadlhkfd, zgwnjwrcud - pjyyilgoni) View more	-	11 Jul 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis